Versiti Launches HLA Loss of Heterozygosity Assay
Versiti this week announced the creation of a new assay for transplant patients that detects and characterizes genomic loss of heterozygosity (LOH) in the human leukocyte antigen (HLA) region. The assay, from the Versiti Histocompatibility Lab, consists of flow cytometric enrichment of a patient's cancer cells, followed by genomic analysis. Versiti uses two separate genomic analysis methods to better ensure accurate detection of HLA LOH. The company has partnered with Seattle-based HematoLogics to identify and isolate abnormal cells in relapse samples via flow cytometry and cell sorting.